IL281370A - 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) - Google Patents

1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Info

Publication number
IL281370A
IL281370A IL281370A IL28137021A IL281370A IL 281370 A IL281370 A IL 281370A IL 281370 A IL281370 A IL 281370A IL 28137021 A IL28137021 A IL 28137021A IL 281370 A IL281370 A IL 281370A
Authority
IL
Israel
Prior art keywords
ripk1
inhibitors
receptor
protein kinase
interacting protein
Prior art date
Application number
IL281370A
Other languages
English (en)
Hebrew (he)
Inventor
William J Pitts
John E Macor
Junqing Guo
Jie Chen
Guanglin Luo
Sing-Yuen Sit
Carolyn Diane Dzierba
Amy C Hart
Original Assignee
Bristol Myers Squibb Co
William J Pitts
John E Macor
Junqing Guo
Jie Chen
Guanglin Luo
Sit Sing Yuen
Carolyn Diane Dzierba
Amy C Hart
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co, William J Pitts, John E Macor, Junqing Guo, Jie Chen, Guanglin Luo, Sit Sing Yuen, Carolyn Diane Dzierba, Amy C Hart filed Critical Bristol Myers Squibb Co
Publication of IL281370A publication Critical patent/IL281370A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/05—Isotopically modified compounds, e.g. labelled

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Cardiology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
IL281370A 2018-09-13 2021-03-09 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1) IL281370A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862730602P 2018-09-13 2018-09-13
PCT/US2019/050719 WO2020056072A1 (en) 2018-09-13 2019-09-12 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Publications (1)

Publication Number Publication Date
IL281370A true IL281370A (en) 2021-04-29

Family

ID=68073171

Family Applications (1)

Application Number Title Priority Date Filing Date
IL281370A IL281370A (en) 2018-09-13 2021-03-09 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)

Country Status (14)

Country Link
US (1) US12172975B2 (cg-RX-API-DMAC7.html)
EP (1) EP3849968B1 (cg-RX-API-DMAC7.html)
JP (1) JP7599411B2 (cg-RX-API-DMAC7.html)
KR (1) KR102906523B1 (cg-RX-API-DMAC7.html)
CN (1) CN112673000B (cg-RX-API-DMAC7.html)
AU (1) AU2019337612A1 (cg-RX-API-DMAC7.html)
BR (1) BR112021004385A2 (cg-RX-API-DMAC7.html)
CA (1) CA3112735A1 (cg-RX-API-DMAC7.html)
EA (1) EA202190718A1 (cg-RX-API-DMAC7.html)
ES (1) ES2936481T3 (cg-RX-API-DMAC7.html)
IL (1) IL281370A (cg-RX-API-DMAC7.html)
MX (1) MX2021002509A (cg-RX-API-DMAC7.html)
SG (1) SG11202102405YA (cg-RX-API-DMAC7.html)
WO (1) WO2020056072A1 (cg-RX-API-DMAC7.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors
US11744824B2 (en) * 2020-09-15 2023-09-05 1ST Biotherapeutics, Inc. 2-amino-3-carbonyl imidazopyridine and pyrazolopyridine compounds
AR123793A1 (es) 2020-10-19 2023-01-11 Bristol Myers Squibb Co Compuestos de triazolopiridinilo como inhibidores de quinasas
WO2025106362A1 (en) * 2023-11-16 2025-05-22 Merck Sharp & Dohme Llc Ripk1 inhibitors and methods of use

Family Cites Families (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7872014B2 (en) 2003-07-23 2011-01-18 Exelixis, Inc. Anaplastic lymphoma kinase modulators and methods of use
JP2008525464A (ja) 2004-12-22 2008-07-17 メモリー・ファーマシューティカルズ・コーポレイション α−7ニコチン性受容体リガンド並びにその製造及び使用
NZ573735A (en) 2006-05-19 2011-10-28 Abbott Lab Cns active fused bicycloheterocycle substituted azabicyclic alkane derivatives
KR101061599B1 (ko) 2008-12-05 2011-09-02 한국과학기술연구원 비정상 세포 성장 질환의 치료를 위한 단백질 키나아제 저해제인 신규 인다졸 유도체, 이의 약학적으로 허용가능한염 및 이를 유효성분으로 함유하는 약학적 조성물
WO2010068287A2 (en) 2008-12-11 2010-06-17 Angion Biomedica Corp. Small molecule modulators of hepatocyte growth factor (scatter factor) activity
ES2458872T3 (es) 2009-04-30 2014-05-07 Novartis Ag Derivados de imidazol y su uso como moduladores de quinasas dependientes de ciclina
US8455516B2 (en) 2010-01-15 2013-06-04 Touro University HIV-1 fusion inhibitors and methods
KR20130077390A (ko) * 2011-12-29 2013-07-09 제이더블유중외제약 주식회사 단백질 키나아제 저해활성을 가지는 6-아미노-3-카복스아미도인다졸 유도체
EA024939B1 (ru) 2012-02-21 2016-11-30 Ацьенде Кимике Рьюните Анджелини Франческо А.К.Р.А.Ф. С.П.А. 1h-индазол-3-карбоксамидные соединения в качестве ингибиторов гликогенсинтазы киназы 3-бета
WO2013124169A1 (en) 2012-02-21 2013-08-29 Aziende Chimiche Riunite Angelini Francesco A.C.R.A.F. S.P.A. Use of 1h-indazole-3-carboxamide compounds as glycogen synthase kinase 3 beta inhibitors
US9783573B2 (en) 2012-09-18 2017-10-10 Bristol-Myers Squibb Company IAP antagonists
CN104781251B (zh) * 2012-11-08 2016-12-14 百时美施贵宝公司 可作为激酶调节剂的经双环杂环取代的吡啶基化合物
BR112016021626A2 (pt) 2014-03-20 2018-05-15 Samumed, Llc indazol-3-carboxamidas 5-substituídas e preparação e uso das mesmas
US10933068B2 (en) 2016-05-26 2021-03-02 Sonic Master Limited Modulators of DUX4 for regulation of muscle function
LT3580220T (lt) 2017-02-13 2021-12-27 Bristol-Myers Squibb Company Aminotriazolopiridinai, kaip kinazės inhibitoriai
CN111566103B (zh) 2017-10-30 2023-06-23 百时美施贵宝公司 作为激酶抑制剂的氨基咪唑并吡嗪
US11618753B2 (en) 2018-01-26 2023-04-04 Bristol-Myers Squibb Company Aminopyrrolotriazines as kinase inhibitors
KR102793119B1 (ko) 2018-09-13 2025-04-07 브리스톨-마이어스 스큅 컴퍼니 키나제 억제제로서의 인다졸 카르복스아미드
US12275721B2 (en) 2019-10-03 2025-04-15 Bristol-Myers Squibb Company Indazole carboxamides as kinase inhibitors

Also Published As

Publication number Publication date
KR102906523B1 (ko) 2025-12-30
BR112021004385A2 (pt) 2021-07-20
CN112673000B (zh) 2024-10-18
ES2936481T3 (es) 2023-03-17
MX2021002509A (es) 2021-04-28
JP7599411B2 (ja) 2024-12-13
WO2020056072A1 (en) 2020-03-19
JP2022500418A (ja) 2022-01-04
CA3112735A1 (en) 2020-03-19
EP3849968A1 (en) 2021-07-21
CN112673000A (zh) 2021-04-16
KR20210060517A (ko) 2021-05-26
SG11202102405YA (en) 2021-04-29
US20220380335A1 (en) 2022-12-01
EP3849968B1 (en) 2022-12-21
US12172975B2 (en) 2024-12-24
EA202190718A1 (ru) 2021-07-01
AU2019337612A1 (en) 2021-05-13

Similar Documents

Publication Publication Date Title
IL287136A (en) Receptor inhibitors - interacting with protein kinase 1
IL282179A (en) Protein tyrosine phosphatase inhibitors
IL283639A (en) Kif18a inhibitors
EP3866927A4 (en) Indane derivatives as hypoxia inducible factor-2(alpha) inhibitors
SG11202102405YA (en) 1h-indazole carboxamides as receptor-interacting protein kinase 1 inhibitors (ripk1)
DK3833348T3 (da) Transglutaminase 2 (TG2)-inhibitorer
IL280950A (en) Inhibitors of keap1-nrf2 protein-protein interaction
DK3837258T3 (da) Dimethyl amino azetidine amides as jak inhibitors
EP3804707A4 (en) KINASE INHIBITOR
MA52004A (fr) Inhibiteurs d'o-glycoprotéine-2-acétamido-2-désoxy-3-d-glycopyranosidase
MA49006A (fr) Inhibiteurs d'ip6k
DK3288931T4 (da) Visse proteinkinaseinhibitorer
DK3737402T5 (da) Modificeret protein
IL281371A (en) Indazole carboxamides as kinase inhibitors
GB2586430B (en) Host aware update write
HUE056885T2 (hu) CREB-kötõ fehérjék inhibitorai
DK3569878T3 (da) Fladhovedet skrue
PL4010330T3 (pl) Pochodne chinoliny jako inhibitory kinazy białkowej
IL281514A (en) O-glycoprotein-2-acetamido-2-deoxy-3-d-glucopyranosidase inhibitors
EP3768272A4 (en) JAK HEMMER
EP3555092A4 (en) PROTEIN KINASE INHIBITORS
DK3452484T3 (da) Visse protein-kinase-inhibitorer
HRP20260316T1 (hr) Postupak akvakulture
PL3594746T3 (pl) Uchwyt magnetyczny
EP3476848A4 (en) BENZOFURANE-PYRAZOLE-AMINE PROTEIN KINASE INHIBITOR